Abliva AB Publishes 2023 Annual Report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the English version of the Annual report for 2023 is now available on the company’s website, www.abliva.com.

The Annual report is also attached below.